Future research is focused on understanding the complex mechanisms of resistance and identifying new therapeutic targets. Advances in genomic profiling and personalized medicine are expected to play a crucial role in developing more effective treatments for EGFR-mutant cancers. Additionally, exploring combination therapies and novel inhibitors will be vital in overcoming resistance and improving patient outcomes.